Icon (NASDAQ:ICLR) Price Target Raised to $130.00

Icon (NASDAQ:ICLR) had its target price upped by JPMorgan Chase & Co. from $120.00 to $130.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential downside of 3.72% from the company’s current price.

ICLR has been the topic of several other reports. Zacks Research lowered shares of Icon from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. Weiss Ratings lowered shares of Icon from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 18th. TD Cowen raised shares of Icon from a “hold” rating to a “buy” rating and cut their price target for the stock from $183.00 to $120.00 in a report on Wednesday, February 18th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Icon in a report on Friday. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $126.00 price target on shares of Icon in a report on Friday. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $153.87.

Icon Stock Down 1.3%

ICLR stock traded down $1.78 during trading on Friday, reaching $135.02. 353,224 shares of the company traded hands, compared to its average volume of 1,587,411. Icon has a 12 month low of $66.57 and a 12 month high of $211.00. The business has a 50 day simple moving average of $112.28 and a 200 day simple moving average of $141.50. The company has a market capitalization of $10.90 billion, a price-to-earnings ratio of 21.92, a price-to-earnings-growth ratio of 3.09 and a beta of 1.23. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06.

Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, May 27th. The medical research company reported $2.52 earnings per share for the quarter, missing analysts’ consensus estimates of $2.95 by ($0.43). Icon had a net margin of 7.40% and a return on equity of 10.58%. The company had revenue of $2.11 billion for the quarter, compared to the consensus estimate of $1.98 billion. During the same period in the previous year, the business earned $3.43 EPS. Icon’s revenue for the quarter was up 2.5% compared to the same quarter last year. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. On average, equities research analysts anticipate that Icon will post 11.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Icon

Several institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP boosted its holdings in Icon by 26.6% in the third quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock worth $811,499,000 after acquiring an additional 975,268 shares in the last quarter. Orbis Allan Gray Ltd boosted its holdings in Icon by 1.8% in the fourth quarter. Orbis Allan Gray Ltd now owns 4,214,661 shares of the medical research company’s stock worth $767,996,000 after acquiring an additional 75,843 shares in the last quarter. Invesco Ltd. boosted its holdings in Icon by 9.6% in the fourth quarter. Invesco Ltd. now owns 3,756,896 shares of the medical research company’s stock worth $684,582,000 after acquiring an additional 329,266 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Icon by 10.3% during the first quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company’s stock worth $366,481,000 after purchasing an additional 310,236 shares during the period. Finally, Franklin Resources Inc. lifted its holdings in shares of Icon by 8.7% during the fourth quarter. Franklin Resources Inc. now owns 2,993,336 shares of the medical research company’s stock worth $545,410,000 after purchasing an additional 239,808 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.